Introduction
Elafibranor is a peroxisome proliferator-activated receptor (PPAR)-alpha/delta agonist approved for primary biliary cholangitis (PBC) second-line treatment. ELFINITY is an ongoing global, prospective, non-interventional phase IV study (NCT06447168) assessing real-world effectiveness and safety of elafibranor.
Aims & Methods
ELFINITY will recruit ~424 patients receiving elafibranor 80 mg/day in real-world settings, to be followed for up to 5 years. Here, we present Month 3 data. Change from baseline (CfB) in alkaline phosphatase (ALP), biochemical response (ALP <1.67× upper limit of normal [ULN] with ≥15% reduction from baseline, and total bilirubin ≤ULN) and ALP normalisation were reported at Month 3. A sub-group analysis was conducted to evaluate obeticholic acid (OCA)-experienced patients in ALP categories (<1, 1–<1.67, 1.67–< 3 and ≥3× ULN) at baseline and at Month 3. Moderate-to-severe (mod–sev) fatigue was defined as PBC-40 Fatigue ≥29 or Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue (scores converted to PROMIS Fatigue Short Form 13a [FACIT-Fatigue] T-scores) T-score ≥60, and mod–sev pruritus as PBC-40 Itch ≥7, Worst-Itch Numeric Rating Score (WI NRS) ≥4 or 5-D Itch ≥12. Patients with mod–sev symptoms achieving minimum clinically important differences (MCID) were reported (improvements PBC-40 Fatigue ≥5, PROMIS Fatigue Short Form 13a [FACIT-Fatigue] T-score ≥3, PBC-40 Itch ≥1.5, WI NRS ≥1.8 and 5-D Itch ≥3). Patients receiving ≥1 dose were assessed. Completion of patient-reported outcomes instruments was not mandatory; missing data were not imputed.
Results
As of October 2025, 55 patients were included in this analysis; 53 received ≥1 dose. Of patients with baseline data, 27/51 (53%) had ALP ≥1.67× ULN. Mean (SD) ALP CfB to Month 3 was –0.7× ULN (0.7). At Month 3, 28/51 (55%) had biochemical response and 11/49 (22%) with baseline ALP >ULN had ALP normalisation; 3 maintained normal baseline ALP to Month 3. Of 20 patients with ALP 1–1.67× ULN at baseline, 8 (40%) had ALP normalisation at Month 3. Of OCA-experienced patients, 7 improved and 1 worsened by one ALP category at Month 3; 8 maintained the same category. At baseline, 25/44 (57%) patients had mod–sev fatigue by PBC-40 Fatigue and 11/44 (25%) by PROMIS Fatigue Short Form 13a (FACIT-Fatigue) T-score. In these patients, 8/14 (57%) improved ≥MCID in PBC-40 Fatigue and 3/6 (50%) in PROMIS Fatigue Short Form 13a (FACIT-Fatigue) T-score at Month 3. Baseline mod–sev pruritus was reported in 9/44 (20%) patients by PBC-40 Itch, 13/44 (30%) by WI NRS and 14/43 (33%) by 5-D Itch. Of these, 3/3 (100%) improved ≥MCID in PBC-40 Itch, 3/3 (100%) in WI NRS and 6/8 (75%) in 5-D Itch at Month 3. By Month 3, 6 patients discontinued. 26/53 (49%) had TEAEs, none of which were serious/severe. TEAEs occurring in ≥5 patients included fatigue (n=6), headache (n=5), diarrhoea (n=5) and nausea (n=5).
Conclusion
In this Month 3 interim analysis, elafibranor led to rapid improvements in ALP and both fatigue and pruritus, and was well tolerated, suggesting elafibranor is effective in real-world practice.
Disclosure
JMS: Consultant honoraria from 89Bio, Akero, Alexion, Altimmune, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, E-Therapeutics, Gilead, GSK, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kriya Therapeutics, Merck, MSD, Novo Nordisk, Pfizer, Roche and Vantage Biosciences LtD; Speaker honoraria from AbbVie, Boehringer Ingelheim, Eli Lilly, Gilead, Ipsen, Madrigal Pharmaceuticals, MSD, Novo Nordisk and Opella; Received travel support from Boehringer Ingelheim, Ipsen; Stockholder of Hepta Bio and HepaCure Pharma.
PF: Advisory board for Dr. Falk Pharma GmbH; research/clinical trial grants: lntercept Pharmaceuticals, Inc., Janssen Research and Development, Pliant Therapeutics Inc., Gilead Sciences, Inc., Ipsen Pharma Austria GmbH and Dr. Falk Pharma GmbH; Speaker/consulting fees from Sanofi-Aventis GmbH, Gilead Sciences, Inc., Merz Pharma Austria GmbH, Takeda Pharma Ges.m.b.H., Roche Austria GmbH, Ipsen Pharma Austria GmbH, Dr. Falk Pharma GmbH. Two patents in Norucholic Acid (norUdCA).
KVK: Received grants from Akero, Boehringer Ingelheim, Boston Pharmaceuticals, Corcept, Gilead, GlaxoSmithKline, Ipsen, Madrigal, Mirum, Novo Nordisk, Zydus, and 89Bio; Received royalties or licenses from UpToDate; Received consulting fees from Boehringer Ingelheim, Gilead, Inipharm, Intercept, Ipsen, Madrigal, Mirum, Zydus, and 89Bio; Received payment or honoraria from Gilead, Ipsen, Madrigal, Novo Nordisk, and Salix; Stock options in Inipharm.
AM: Received grants or contracts from Ipsen, Gilead and Madrigal Pharmaceuticals; Received support for attending meetings and/or travel from Ipsen.
SJ, CP, MS: Employees and shareholders of Ipsen.
PT: Employee of Ipsen; Shareholder of Gilead and GSK.
MT: Received grant support from Albireo, Alnylam, CymaBay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx; Received honoraria for consulting from AbbVie, Albireo, Agomab, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Janssen, Mirum, MSD, Novartis, Phenex, Pliant, ProQR Therapeutics, Regulus, Siemens and Shire; Received speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, MSD and Madrigal; Received travel support from AbbVie, Falk, Gilead, Intercept, Ipsen and Janssen; Co-inventor of patents on the medical use of 24-norursodeoxycholic acid filed by the Medical University of Graz.